TP53 and osteosarcoma: In the present study, to assess the anti-osteosarcoma potential of exogenous AKG, two primary osteosarcoma cell lines harboring TP53 mutations were used, i.e., Saos-2 (p53-null cell line) and HOS (p53 mutant).